Feasibility Trial on ACURATE™ Transapical Implantation in Patients With Severe Symptomatic Aortic Stenosis (2009-01) (TA-FIM)
Feasibility Trial on ACURATE™ Transapical Implantation in Patients With Severe Symptomatic Aortic Stenosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bad Nauheim, Germany, 61231
- Kerckhoff Klinik GmbH
-
Essen, Germany, 45122
- Universitätsklinikum Essen Westdeutsches Herzzentrum Essen
-
Freiburg, Germany
- Universitätsklinikum Freiburg Herz- und Gefäßchirurgie
-
Hamburg, Germany, 20246
- Universitätsklinikum Hamburg-Eppendorf Klinik für Herz-und Gefässchirurgie
-
Leipzig, Germany, 04289
- Herzzentrum Leipzig GmbH
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients older than 75 years;
- Additive EuroSCORE > 9 and/or STS > 9%;
- Severe symptomatic AS assessed by echocardiography, documented by a derived mean gradient > 40mmHg,and a native Aortic Valve Area (AVA) < 0.8 cm² or Aortic Valve Area Index (AVAI) < 0.6 cm²/m²;
- NYHA Functional Class > II;
- Aortic annulus (AAn) diameters between and including 21 mm up to 27 mm (21mm ≤ AAn ≤27mm) by transoesophageal echocardiography;
- Sinotubular junction (STJ) higher than 1,1times the native aortic annulus diameter (AAn) [STJ>1.1xAAn] AND STJ<45mm by transoesophageal echocardiography;
- Patient understands the implications of participating in the study and provides signed informed consent
Exclusion Criteria:
- Congenital unicuspid or bicuspid aortic valve;
- Severe eccentricity of calcification;
- Severe mitral regurgitation (> 2°);
- Pre-existing prosthetic heart valve in any position and /or prosthetic ring;
- Severe transapical access problem, non-reachable LV apex;
- Previous surgery of the LV using a patch, such as the Dor procedure;
- Presence of apical LV thrombus;
- Echocardiographic evidence of intracardiac mass, thrombus, or vegetation;
- Acute Myocardial Infarction (AMI) within 1 month prior to the procedure;
- PCI within 1 month prior to the procedure;
- Previous Transient Ischemic Accident (TIA) or stroke in the last 3 months;
- Untreated clinically significant CAD requiring revascularization;
- Hemodynamic instability: systolic pressure <90mmHg without afterload reduction, shock, need for inotropic support or intra-aortic balloon pump;
- Severe left ventricular dysfunction with a LV Ejection Fraction (LVEF) < 25% by echocardiography;
- Calcified pericardium;
- Septal hypertrophy;
- Primary Hypertrophic Obstructive Cardiomyopathy (HOCM);
- Active infection, endocarditis or pyrexia;
- Active peptic ulcer or Gastrointestinal (GI) bleeding within the past 3 months;
- Significant hepatic involvement (Child > B);
- Major lung disease (FEV < 0.8 or FEV1% < 30% of normal);
- Pulmonary hypertension;
- History of bleeding diathesis or coagulopathy;
- Hematologic disorder (WBC<3000mm3, Hb<9g/dL, platelet count <50000 cells/ mm3);
- Serum creatinine level greater than 3.0 mg/dL or chronic renal failure requiring dialysis;
- Neurological disease severely affecting ambulation or daily functioning, including dementia;
- Other procedure scheduled at the same time, whether surgery or percutaneous approach;
- Emergency procedure;
- Life expectancy < 12 months due to non-cardiac co-morbid conditions;
- Known hypersensitivity/contraindication to any study medication, contrast media, or nitinol;
- Currently participating in an investigational drug or another device study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: ACURATE TA™
Patients implanted with ACURATE TA™ Bioprosthesis
|
ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement surgery.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety endpoint
Time Frame: 30 days
|
Rate of Major Adverse Valve-Related Events (MAVRE) related to ACURATE
|
30 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Performance endpoint
Time Frame: Up to 24-hours post-procedure
|
Stable ACURATE placement at intended site as assessed by angiography
|
Up to 24-hours post-procedure
|
|
Performance endpoint
Time Frame: Up to 24-hours post-procedure
|
Adequate ACURATE device function as assessed by echocardiography
|
Up to 24-hours post-procedure
|
|
Mortality
Time Frame: 30 days, 60 days, 3 months, 6 months and 12 months
|
Freedom from Death at follow-up
|
30 days, 60 days, 3 months, 6 months and 12 months
|
|
MAVRE at follow-up
Time Frame: discharge or 7 days, 3 months, 6 months and 12 months
|
Rate of MAVRE at follow-up
|
discharge or 7 days, 3 months, 6 months and 12 months
|
|
MACCE or Major Adverse Cardiac and Cerebrovascular Event
Time Frame: 1 month, 3 months, 6 months and 12 months
|
Rate of MACCE at follow up
|
1 month, 3 months, 6 months and 12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Friedrich Mohr, Professor, Herzzentrum Leipzig GmbH
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2009-01
- DE/CA84/73-KL-30-09 (Other Identifier: Landesdirektion Sachsen - Freistaat Sachsen)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.